CytomX Therapeutics Inc (6C1 F) stock market data APIs

€0.7799 0(0%)
as of February 14, 2025

CytomX Therapeutics Inc Financial Data Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Prev. Close 0.7799
Open 0.7799
High 0.7799
Low 0.7799
52 wk Range 0.7135-4.402
Market Cap 60 572 K
P/E Ratio 5.16
Shares Outstanding 78 259 K
Revenue 127 M
EPS -0.3
Beta 1.005

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get CytomX Therapeutics Inc data using free add-ons & libraries


Get CytomX Therapeutics Inc Fundamental Data

CytomX Therapeutics Inc Fundamental data includes:

  • Net Revenue: 127 M
  • EBITDA: 8 551 K
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get CytomX Therapeutics Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2021-08-05
  • EPS/Forecast: -0.32
GET THE PACKAGE

Get CytomX Therapeutics Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

CytomX Therapeutics Inc News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat